FDA approvals for these drugs could translate to billions of dollars for a few companies.
News & Analysis: Ardelyx
The buyers for its secondary stock offering weren't willing to pay up for the biotech.
The stock is down almost 20% after the company announced it was raising cash two different ways.
Good news from clinical studies and a scrapped acquisition help powered these biotech stocks to huge gains this week.
Positive phase 3 data for the biotech's irritable bowel syndrome drug, tenapanor, sends shares higher.
Even as banks took the spotlight, these stocks gained ground. Find out why.
Shares of Synergy are down, but things are looking up for this GI gem
These five small-cap growth stocks could soar in 2015. Here's why.
Ardelyx Inc. shares fell on news that its kidney disease drug resulted in a higher incidence of diarrhea than anticipated.